Endo has given negative returns year-to-date
On October 5, Endo International (ENDP) fell by 5.32% on profit booking, breaking its three-day upward movement. As per the press release on October 1, the company announced “that it has completed the previously announced acquisition of a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas from a subsidiary of Aspen Holdings, a leading publicly-traded South African company that supplies branded and generic products in more than 150 countries.”
The above graph reflects the performance of ENDP with the Health Care Select Sector SPDR ETF (XLV) and the SDR S&P 500 (ETF). As of September 30, ENDP’s YTD (year-to-date) returns were -3.94%, XLV’s YTD returns were -3.14%, and SPY’s YTD returns stood at -6.79%. Industry peers Zoetis (ZTS) and Mylan (MYL) had YTD returns of -4.30% and -28.58%, respectively.
ENDP’s best performance of 9.91% returns came in July 2015 and its worst performance of -12.04% returns came in August 2015.
Valuations and moving averages of ENDP
The price-to-book value of ENDP on October 5 stood at 2.28x as compared to XLV’s industry average of 5.69x, indicating that the stock is trading below the industry average. The stock closed at $67.28 and was trading below its 20-day, 50-day, and 100-day moving averages. ENDP has a weight of 0.58% in XLV’s portfolio.